<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>MK-0616 (Enlicitide Decanoate) - Comprehensive Drug Profile</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            min-height: 100vh;
            padding: 20px;
        }
        
        .container {
            max-width: 1400px;
            margin: 0 auto;
            background: white;
            border-radius: 20px;
            box-shadow: 0 20px 60px rgba(0,0,0,0.3);
            overflow: hidden;
        }
        
        .header {
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            color: white;
            padding: 40px;
            position: relative;
            overflow: hidden;
        }
        
        .header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -10%;
            width: 40%;
            height: 200%;
            background: rgba(255,255,255,0.08);
            transform: rotate(45deg);
        }
        
        .drug-title {
            position: relative;
            z-index: 1;
        }
        
        .drug-name {
            font-size: 48px;
            font-weight: bold;
            margin-bottom: 10px;
            text-shadow: 2px 2px 4px rgba(0,0,0,0.2);
        }
        
        .drug-generic {
            font-size: 28px;
            opacity: 0.95;
            margin-bottom: 10px;
        }
        
        .drug-subtitle {
            font-size: 22px;
            opacity: 0.9;
            margin-bottom: 5px;
        }
        
        .drug-company {
            font-size: 20px;
            opacity: 0.85;
        }
        
        .status-badge {
            display: inline-block;
            background: linear-gradient(135deg, #ff9800 0%, #f57c00 100%);
            padding: 10px 20px;
            border-radius: 25px;
            margin-top: 20px;
            font-weight: 600;
            font-size: 16px;
            box-shadow: 0 4px 10px rgba(0,0,0,0.2);
            animation: pulse 2s infinite;
        }
        
        @keyframes pulse {
            0%, 100% { transform: scale(1); }
            50% { transform: scale(1.05); }
        }
        
        .first-in-class {
            display: inline-block;
            background: linear-gradient(135deg, #4caf50 0%, #2e7d32 100%);
            padding: 8px 16px;
            border-radius: 20px;
            margin-left: 10px;
            font-size: 14px;
            font-weight: 600;
        }
        
        .nav-tabs {
            display: flex;
            background: #f8f9fa;
            border-bottom: 2px solid #e0e0e0;
            overflow-x: auto;
        }
        
        .nav-tab {
            padding: 15px 30px;
            cursor: pointer;
            border: none;
            background: transparent;
            font-size: 16px;
            font-weight: 600;
            color: #666;
            transition: all 0.3s;
            white-space: nowrap;
        }
        
        .nav-tab:hover {
            background: rgba(0, 83, 156, 0.1);
        }
        
        .nav-tab.active {
            color: #00539C;
            border-bottom: 3px solid #00539C;
            margin-bottom: -2px;
        }
        
        .content-area {
            padding: 40px;
        }
        
        .tab-content {
            display: none;
            animation: fadeIn 0.5s;
        }
        
        .tab-content.active {
            display: block;
        }
        
        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }
        
        .game-changer-banner {
            background: linear-gradient(135deg, #4caf50 0%, #2e7d32 100%);
            color: white;
            padding: 25px;
            border-radius: 15px;
            margin-bottom: 30px;
            box-shadow: 0 5px 20px rgba(76, 175, 80, 0.3);
        }
        
        .game-changer-banner h3 {
            font-size: 24px;
            margin-bottom: 10px;
        }
        
        .mechanism-section {
            background: linear-gradient(135deg, #e3f2fd 0%, #bbdefb 100%);
            border-radius: 15px;
            padding: 30px;
            margin-bottom: 30px;
        }
        
        .mechanism-title {
            font-size: 24px;
            color: #333;
            margin-bottom: 20px;
            display: flex;
            align-items: center;
        }
        
        .mechanism-icon {
            width: 40px;
            height: 40px;
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            margin-right: 15px;
            color: white;
            font-weight: bold;
        }
        
        .mechanism-content {
            line-height: 1.8;
            color: #555;
        }
        
        .mechanism-highlight {
            background: rgba(0, 83, 156, 0.15);
            padding: 2px 6px;
            border-radius: 4px;
            font-weight: 600;
            color: #00539C;
        }
        
        .dosing-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 20px;
            margin: 30px 0;
        }
        
        .dosing-card {
            background: white;
            border: 2px solid #e0e0e0;
            border-radius: 12px;
            padding: 20px;
            text-align: center;
            transition: all 0.3s;
            position: relative;
        }
        
        .dosing-card.optimal {
            border-color: #4caf50;
            background: linear-gradient(135deg, rgba(76, 175, 80, 0.05) 0%, rgba(46, 125, 50, 0.05) 100%);
            transform: scale(1.05);
        }
        
        .dosing-card.optimal::after {
            content: '‚úì Optimal';
            position: absolute;
            top: -10px;
            right: 10px;
            background: #4caf50;
            color: white;
            padding: 5px 10px;
            border-radius: 15px;
            font-size: 12px;
            font-weight: 600;
        }
        
        .dosing-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.1);
        }
        
        .dosing-dose {
            font-size: 32px;
            font-weight: bold;
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }
        
        .dosing-efficacy {
            font-size: 24px;
            font-weight: bold;
            color: #4caf50;
            margin: 10px 0;
        }
        
        .dosing-detail {
            font-size: 14px;
            color: #666;
        }
        
        .comparison-grid {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 30px;
            margin: 30px 0;
        }
        
        .comparison-card {
            background: white;
            border-radius: 12px;
            padding: 25px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .comparison-card h4 {
            color: #00539C;
            margin-bottom: 15px;
            font-size: 18px;
        }
        
        .comparison-card ul {
            list-style: none;
            padding: 0;
        }
        
        .comparison-card li {
            padding: 8px 0;
            border-bottom: 1px solid #f0f0f0;
            display: flex;
            align-items: center;
        }
        
        .comparison-card li:last-child {
            border-bottom: none;
        }
        
        .advantage-icon {
            color: #4caf50;
            margin-right: 10px;
            font-size: 20px;
        }
        
        .consideration-icon {
            color: #ff9800;
            margin-right: 10px;
            font-size: 20px;
        }
        
        .timeline-container {
            margin: 30px 0;
            padding: 30px;
            background: #f8f9fa;
            border-radius: 15px;
        }
        
        .timeline-header {
            font-size: 20px;
            font-weight: bold;
            margin-bottom: 30px;
            color: #333;
        }
        
        .timeline {
            position: relative;
            padding: 20px 0;
        }
        
        .timeline-line {
            position: absolute;
            left: 50%;
            top: 0;
            bottom: 0;
            width: 3px;
            background: linear-gradient(180deg, #00539C 0%, #003A70 100%);
        }
        
        .timeline-item {
            position: relative;
            margin-bottom: 40px;
            display: flex;
            align-items: center;
        }
        
        .timeline-item:nth-child(odd) {
            flex-direction: row-reverse;
        }
        
        .timeline-content {
            width: 45%;
            background: white;
            padding: 20px;
            border-radius: 10px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
            position: relative;
            transition: all 0.3s;
            cursor: pointer;
        }
        
        .timeline-content:hover {
            transform: scale(1.02);
            box-shadow: 0 10px 30px rgba(0,0,0,0.15);
        }
        
        .timeline-content.future {
            background: linear-gradient(135deg, #fff3cd 0%, #ffeaa7 100%);
        }
        
        .timeline-dot {
            position: absolute;
            left: 50%;
            transform: translateX(-50%);
            width: 20px;
            height: 20px;
            background: #00539C;
            border: 4px solid white;
            border-radius: 50%;
            box-shadow: 0 2px 10px rgba(0,0,0,0.2);
            z-index: 1;
        }
        
        .timeline-dot.future {
            background: #ff9800;
        }
        
        .timeline-date {
            font-weight: bold;
            color: #00539C;
            margin-bottom: 5px;
        }
        
        .timeline-title {
            font-size: 16px;
            font-weight: 600;
            margin-bottom: 5px;
        }
        
        .timeline-description {
            font-size: 14px;
            color: #666;
            line-height: 1.5;
        }
        
        .timeline-details {
            display: none;
            margin-top: 15px;
            padding-top: 15px;
            border-top: 1px solid #e0e0e0;
            font-size: 13px;
            color: #555;
        }
        
        .timeline-content:hover .timeline-details {
            display: block;
        }
        
        .trials-table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            background: white;
            border-radius: 10px;
            overflow: hidden;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .trials-table thead {
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            color: white;
        }
        
        .trials-table th {
            padding: 15px;
            text-align: left;
            font-weight: 600;
        }
        
        .trials-table td {
            padding: 15px;
            border-bottom: 1px solid #e0e0e0;
        }
        
        .trials-table tbody tr:hover {
            background: #f8f9fa;
        }
        
        .trial-phase {
            display: inline-block;
            padding: 4px 10px;
            border-radius: 20px;
            font-size: 12px;
            font-weight: 600;
        }
        
        .phase-1 { background: #e3f2fd; color: #1976d2; }
        .phase-2 { background: #f3e5f5; color: #7b1fa2; }
        .phase-3 { background: #e8f5e9; color: #388e3c; }
        
        .trial-status {
            display: inline-block;
            padding: 4px 10px;
            border-radius: 12px;
            font-size: 12px;
            font-weight: 600;
        }
        
        .status-complete { background: #d4edda; color: #155724; }
        .status-ongoing { background: #fff3cd; color: #856404; }
        
        .efficacy-chart {
            background: white;
            border-radius: 15px;
            padding: 30px;
            margin: 20px 0;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .chart-title {
            font-size: 20px;
            font-weight: bold;
            margin-bottom: 20px;
            color: #333;
        }
        
        .bar-chart {
            display: flex;
            align-items: flex-end;
            height: 350px;
            gap: 20px;
            padding: 20px 0;
            justify-content: space-evenly;
        }
        
        .bar-group {
            flex: 0 0 auto;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: flex-end;
            min-width: 80px;
        }
        
        .bar {
            width: 60px;
            background: linear-gradient(180deg, #00539C 0%, #003A70 100%);
            border-radius: 10px 10px 0 0;
            position: relative;
            transition: all 0.3s;
            cursor: pointer;
            animation: growUp 1s ease-out;
        }
        
        @keyframes growUp {
            from { height: 0; }
        }
        
        .bar.optimal {
            background: linear-gradient(180deg, #4caf50 0%, #2e7d32 100%);
        }
        
        .bar.secondary {
            background: linear-gradient(180deg, #9e9e9e 0%, #616161 100%);
        }
        
        .bar.lpa {
            background: linear-gradient(180deg, #ff9800 0%, #f57c00 100%);
        }
        
        .bar:hover {
            transform: scaleY(1.05);
            box-shadow: 0 5px 20px rgba(0, 83, 156, 0.3);
        }
        
        .bar-value {
            position: absolute;
            top: -30px;
            left: 50%;
            transform: translateX(-50%);
            font-weight: bold;
            font-size: 18px;
            color: #00539C;
            white-space: nowrap;
        }
        
        .bar-label {
            margin-top: 10px;
            text-align: center;
            font-size: 13px;
            color: #666;
            max-width: 80px;
        }
        
        .dose-response-curve {
            background: white;
            padding: 30px;
            border-radius: 15px;
            margin: 20px 0;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .safety-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 20px;
            margin: 20px 0;
        }
        
        .safety-card {
            background: linear-gradient(135deg, #fff 0%, #f0f7ff 100%);
            border: 2px solid #e3f2fd;
            border-radius: 12px;
            padding: 20px;
            text-align: center;
            transition: all 0.3s;
        }
        
        .safety-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.1);
            border-color: #00539C;
        }
        
        .safety-percentage {
            font-size: 32px;
            font-weight: bold;
            background: linear-gradient(135deg, #4caf50 0%, #2e7d32 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }
        
        .safety-label {
            font-size: 14px;
            color: #666;
            margin-top: 10px;
        }
        
        .commercial-section {
            background: #f8f9fa;
            border-radius: 15px;
            padding: 30px;
            margin: 20px 0;
        }
        
        .price-projection {
            text-align: center;
            margin: 30px 0;
        }
        
        .price-range {
            font-size: 36px;
            font-weight: bold;
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }
        
        .price-comparison {
            font-size: 16px;
            color: #666;
            margin-top: 10px;
        }
        
        .market-metrics {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            margin: 30px 0;
        }
        
        .metric-card {
            background: white;
            padding: 20px;
            border-radius: 12px;
            text-align: center;
            border-top: 4px solid #00539C;
        }
        
        .metric-value {
            font-size: 28px;
            font-weight: bold;
            color: #00539C;
            margin-bottom: 5px;
        }
        
        .metric-label {
            font-size: 14px;
            color: #666;
        }
        
        .info-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 30px;
            margin: 30px 0;
        }
        
        .info-card {
            background: white;
            border-radius: 15px;
            padding: 25px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .info-card-title {
            font-size: 18px;
            font-weight: bold;
            color: #333;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
        }
        
        .info-icon {
            width: 30px;
            height: 30px;
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            margin-right: 10px;
            color: white;
            font-size: 14px;
        }
        
        .info-list {
            list-style: none;
        }
        
        .info-list li {
            padding: 8px 0;
            border-bottom: 1px solid #f0f0f0;
            color: #666;
            font-size: 14px;
        }
        
        .info-list li:last-child {
            border-bottom: none;
        }
        
        .highlight-box {
            background: linear-gradient(135deg, rgba(0, 83, 156, 0.1) 0%, rgba(0, 58, 112, 0.1) 100%);
            border-left: 4px solid #00539C;
            padding: 20px;
            border-radius: 8px;
            margin: 20px 0;
        }
        
        .highlight-title {
            font-weight: bold;
            color: #00539C;
            margin-bottom: 10px;
        }
        
        .highlight-content {
            color: #555;
            line-height: 1.6;
        }
        
        .pipeline-timeline {
            position: relative;
            padding: 20px 0;
            margin: 30px 0;
        }
        
        .pipeline-track {
            height: 8px;
            background: #e0e0e0;
            border-radius: 4px;
            position: relative;
        }
        
        .pipeline-progress {
            height: 100%;
            background: linear-gradient(90deg, #00539C 0%, #003A70 100%);
            border-radius: 4px;
            width: 75%;
            position: relative;
            animation: progressGrow 2s ease-out;
        }
        
        @keyframes progressGrow {
            from { width: 0; }
        }
        
        .pipeline-milestone {
            position: absolute;
            top: -40px;
            transform: translateX(-50%);
            text-align: center;
            white-space: nowrap;
        }
        
        .milestone-dot {
            width: 16px;
            height: 16px;
            background: white;
            border: 3px solid #00539C;
            border-radius: 50%;
            margin: 0 auto 5px;
        }
        
        .milestone-label {
            font-size: 12px;
            color: #666;
        }
        
        .adherence-comparison {
            background: #fff3cd;
            border-left: 4px solid #ff9800;
            padding: 20px;
            border-radius: 8px;
            margin: 20px 0;
        }
        
        @media (max-width: 768px) {
            .timeline-item {
                flex-direction: column !important;
            }
            
            .timeline-content {
                width: 90%;
                margin: 0 auto;
            }
            
            .timeline-line {
                left: 20px;
            }
            
            .timeline-dot {
                left: 20px;
            }
            
            .bar-chart {
                height: 250px;
                overflow-x: auto;
            }
            
            .comparison-grid {
                grid-template-columns: 1fr;
            }
        }
    </style>
</head>
<body>
    
    <div class="container">
        <div class="header">
            <div class="drug-title">
                <div class="drug-name">MK-0616</div>
                <div class="drug-generic">Enlicitide Decanoate</div>
                <div class="drug-subtitle">First-in-Class Oral PCSK9 Inhibitor</div>
                <div class="drug-company">Merck & Co., Inc.</div>
                <span class="status-badge">Phase 3 Complete</span>
                <span class="first-in-class">üéØ FIRST ORAL PCSK9i</span>
            </div>
        </div>
        
        <div class="nav-tabs">
            <button class="nav-tab active" onclick="showTab('overview')">Overview</button>
            <button class="nav-tab" onclick="showTab('mechanism')">Mechanism & Dosing</button>
            <button class="nav-tab" onclick="showTab('regulatory')">Regulatory Timeline</button>
            <button class="nav-tab" onclick="showTab('clinical')">Clinical Trials</button>
            <button class="nav-tab" onclick="showTab('safety')">Safety Profile</button>
            <button class="nav-tab" onclick="showTab('commercial')">Commercial</button>
            <button class="nav-tab" onclick="showTab('pipeline')">Pipeline & Future</button>
        </div>
        
        <div class="content-area">
            <!-- Overview Tab -->
            <div id="overview" class="tab-content active">
                <div class="game-changer-banner">
                    <h3>üéØ Game-Changing Innovation</h3>
                    <p>First oral PCSK9 inhibitor - No injections required! Daily tablet provides similar efficacy to injectable monoclonal antibodies (60-65% LDL reduction) with the convenience of oral administration. This could transform PCSK9 inhibition from specialist injectable therapy to primary care oral treatment.</p>
                </div>
                
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üî¨</div>
                            Key Innovation
                        </div>
                        <ul class="info-list">
                            <li>Macrocyclic peptide (MW ~1 kDa)</li>
                            <li>Survives GI degradation through cyclization</li>
                            <li>>90% PCSK9 suppression (mAb-comparable)</li>
                            <li>Acts extracellularly in plasma</li>
                            <li>No CYP metabolism or drug interactions</li>
                            <li>Once-daily oral dosing</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üìä</div>
                            Clinical Performance
                        </div>
                        <ul class="info-list">
                            <li>Phase 3 met primary endpoints (June 2025)</li>
                            <li>60-65% LDL-C reduction at optimal doses</li>
                            <li>>80% patients achieve <70 mg/dL LDL</li>
                            <li>ApoB/non-HDL-C: 45-55% reduction</li>
                            <li>Lp(a): 20-30% reduction</li>
                            <li>14,000-patient outcomes trial ongoing</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üéØ</div>
                            Strategic Advantages
                        </div>
                        <ul class="info-list">
                            <li>First-mover in oral PCSK9 space</li>
                            <li>Broad GP prescribing potential</li>
                            <li>Pharmacy benefit (not medical)</li>
                            <li>No injection site reactions</li>
                            <li>At-home convenience</li>
                            <li>Potentially lower cost than injectables</li>
                        </ul>
                    </div>
                </div>
                
                <div class="comparison-grid">
                    <div class="comparison-card">
                        <h4><span class="advantage-icon">‚úÖ</span> Advantages vs Injectables</h4>
                        <ul>
                            <li><span class="advantage-icon">‚úì</span> No needles or injection training</li>
                            <li><span class="advantage-icon">‚úì</span> At-home self-administration</li>
                            <li><span class="advantage-icon">‚úì</span> No injection site reactions</li>
                            <li><span class="advantage-icon">‚úì</span> Broader prescriber base</li>
                            <li><span class="advantage-icon">‚úì</span> Simpler distribution (pharmacy)</li>
                            <li><span class="advantage-icon">‚úì</span> Potentially lower cost</li>
                        </ul>
                    </div>
                    <div class="comparison-card">
                        <h4><span class="consideration-icon">‚ö†Ô∏è</span> Considerations</h4>
                        <ul>
                            <li><span class="consideration-icon">‚Ä¢</span> Daily dosing vs Q2W/Q6M injections</li>
                            <li><span class="consideration-icon">‚Ä¢</span> Adherence challenges (~50% real-world)</li>
                            <li><span class="consideration-icon">‚Ä¢</span> More frequent than inclisiran</li>
                            <li><span class="consideration-icon">‚Ä¢</span> Requires daily patient action</li>
                            <li><span class="consideration-icon">‚Ä¢</span> GI tolerability in some patients</li>
                            <li><span class="consideration-icon">‚Ä¢</span> No supervised administration</li>
                        </ul>
                    </div>
                </div>
            </div>
            
            <!-- Mechanism & Dosing Tab -->
            <div id="mechanism" class="tab-content">
                <div class="mechanism-section">
                    <div class="mechanism-title">
                        <div class="mechanism-icon">‚öôÔ∏è</div>
                        Mechanism of Action
                    </div>
                    <div class="mechanism-content">
                        Enlicitide decanoate is a <span class="mechanism-highlight">macrocyclic peptide</span> designed as an 
                        <span class="mechanism-highlight">oral PCSK9 inhibitor</span>. Key mechanistic features:
                        <ul style="margin-top: 15px; margin-left: 20px;">
                            <li><strong>Molecular design:</strong> Small cyclic peptide (~1 kDa) engineered for oral bioavailability</li>
                            <li><strong>GI stability:</strong> Survives digestive enzymes through cyclization and structural modifications</li>
                            <li><strong>Target binding:</strong> Binds with high affinity to circulating PCSK9 in plasma</li>
                            <li><strong>Mode of action:</strong> Prevents PCSK9 interaction with LDL receptors on hepatocytes</li>
                            <li><strong>Downstream effects:</strong> Inhibits PCSK9-mediated LDL-R degradation ‚Üí Increased LDL-R recycling ‚Üí Enhanced LDL clearance</li>
                            <li><strong>PCSK9 suppression:</strong> Achieves >90% reduction in free PCSK9 (comparable to mAbs)</li>
                            <li><strong>Extracellular action:</strong> Works in plasma without entering cells (no CYP interactions)</li>
                        </ul>
                        <br>
                        Unlike injectable mAbs (large proteins requiring SC administration) or inclisiran (siRNA silencing gene expression 
                        intracellularly), enlicitide provides <span class="mechanism-highlight">oral PCSK9 inhibition</span> with similar 
                        downstream effects on LDL-R upregulation.
                    </div>
                </div>
                
                <div class="mechanism-section">
                    <div class="mechanism-title">
                        <div class="mechanism-icon">üíä</div>
                        Dosing Regimens & Efficacy
                    </div>
                    <div class="dosing-grid">
                        <div class="dosing-card">
                            <div class="dosing-dose">6 mg</div>
                            <div class="dosing-efficacy">41.2%</div>
                            <div class="dosing-detail">LDL-C reduction<br>Moderate efficacy</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-dose">12 mg</div>
                            <div class="dosing-efficacy">55.7%</div>
                            <div class="dosing-detail">LDL-C reduction<br>Good efficacy</div>
                        </div>
                        <div class="dosing-card optimal">
                            <div class="dosing-dose">18 mg</div>
                            <div class="dosing-efficacy">59.7%</div>
                            <div class="dosing-detail">LDL-C reduction<br>Near-maximal effect</div>
                        </div>
                        <div class="dosing-card optimal">
                            <div class="dosing-dose">30 mg</div>
                            <div class="dosing-efficacy">60.9%</div>
                            <div class="dosing-detail">LDL-C reduction<br>Maximum efficacy</div>
                        </div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Dosing Characteristics</div>
                    <div class="highlight-content">
                        Once-daily oral administration. Tablet formulation designed for GI stability. No dose adjustments 
                        specified for renal/hepatic impairment. Minimal food effect. Rapid onset with LDL-C reductions 
                        within 2 weeks, steady-state by weeks 4-8. Efficacy plateau observed at 18-30 mg doses, 
                        suggesting maximal PCSK9 inhibition achieved.
                    </div>
                </div>
                
                <div class="adherence-comparison">
                    <strong>‚ö†Ô∏è Adherence Consideration:</strong> Real-world adherence to daily medications typically ~50% at 1 year. 
                    Digital adherence tools and patient support programs planned. Compare to inclisiran's guaranteed compliance 
                    via supervised biannual injections. Success depends on managing adherence challenges through technology 
                    and patient engagement.
                </div>
            </div>
            
            <!-- Regulatory Timeline Tab -->
            <div id="regulatory" class="tab-content">
                <div class="timeline-container">
                    <div class="timeline-header">FDA Development Timeline</div>
                    <div class="timeline">
                        <div class="timeline-line"></div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">Pre-2021</div>
                                <div class="timeline-title">Preclinical Development</div>
                                <div class="timeline-description">Macrocyclic peptide optimization</div>
                                <div class="timeline-details">
                                    Extensive work on peptide cyclization, GI stability, and oral bioavailability. 
                                    Developed proprietary formulation to survive digestive enzymes.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">November 2021</div>
                                <div class="timeline-title">Phase 1 Results (AHA 2021)</div>
                                <div class="timeline-description">First human data presented</div>
                                <div class="timeline-details">
                                    Single/multiple ascending doses showed >90% PCSK9 reduction, LDL-C drops up to 65%. 
                                    Established proof-of-concept for oral PCSK9 inhibition.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">March 2022</div>
                                <div class="timeline-title">Phase 2a Completion</div>
                                <div class="timeline-description">Confirmed efficacy in hypercholesterolemia</div>
                                <div class="timeline-details">
                                    Add-on to statins showed ~65% LDL reduction. Safety profile comparable to placebo. 
                                    No GI tolerability issues observed.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">March 6, 2023</div>
                                <div class="timeline-title">Phase 2b Results (ACC 2023)</div>
                                <div class="timeline-description">Dose-response established</div>
                                <div class="timeline-details">
                                    NCT05261126: 381 patients, 41-61% LDL reduction dose-dependent. 
                                    FDA agreement on Phase 3 design obtained. No safety signals.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">August 25, 2023</div>
                                <div class="timeline-title">CORALreef Program Launch</div>
                                <div class="timeline-description">Phase 3 trials initiated</div>
                                <div class="timeline-details">
                                    Three pivotal trials started: Lipids (n=2,700), HeFH (n=300), and Outcomes (n=14,000). 
                                    Largest oral PCSK9 inhibitor program to date.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">June 9, 2025</div>
                                <div class="timeline-title">‚úÖ Positive Phase 3 Results</div>
                                <div class="timeline-description">Primary endpoints met</div>
                                <div class="timeline-details">
                                    CORALreef HeFH and AddOn trials successful. 60-65% LDL reduction confirmed. 
                                    Safety profile maintained. >80% achieved guideline goals.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">July 2025</div>
                                <div class="timeline-title">Pediatric Trial Start</div>
                                <div class="timeline-description">Phase 2/3 in pediatric HeFH</div>
                                <div class="timeline-details">
                                    NCT07058077 initiated for pediatric indication. N=200 patients. 
                                    Expands potential patient population.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content future">
                                <div class="timeline-date">Mid-2026 (Projected)</div>
                                <div class="timeline-title">NDA Filing</div>
                                <div class="timeline-description">FDA submission expected</div>
                                <div class="timeline-details">
                                    Based on LDL-C surrogate endpoint data. Priority review possible given 
                                    first-in-class oral status. 6-12 month review anticipated.
                                </div>
                            </div>
                            <div class="timeline-dot future"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content future">
                                <div class="timeline-date">2027 (Projected)</div>
                                <div class="timeline-title">FDA Approval</div>
                                <div class="timeline-description">First oral PCSK9i launch</div>
                                <div class="timeline-details">
                                    Potential approval for hypercholesterolemia and HeFH. Broad label expected 
                                    similar to existing PCSK9 inhibitors.
                                </div>
                            </div>
                            <div class="timeline-dot future"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content future">
                                <div class="timeline-date">2029 (Projected)</div>
                                <div class="timeline-title">Outcomes Data</div>
                                <div class="timeline-description">CORALreef Outcomes completion</div>
                                <div class="timeline-details">
                                    14,000-patient MACE trial results. Expected to show 15-20% CV risk reduction. 
                                    Will support label expansion and broader reimbursement.
                                </div>
                            </div>
                            <div class="timeline-dot future"></div>
                        </div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Regulatory Status</div>
                    <div class="highlight-content">
                        No clinical holds or CRLs throughout development. FDA agreement on trial designs secured. 
                        Global development aligned with FDA pathway (no separate EMA timeline announced). 
                        Leveraging established PCSK9 regulatory precedent for LDL-based approval. 
                        Manufacturing of complex peptide validated. First-in-class status may expedite review.
                    </div>
                </div>
            </div>
            
            <!-- Clinical Trials Tab -->
            <div id="clinical" class="tab-content">
                <table class="trials-table">
                    <thead>
                        <tr>
                            <th>Trial</th>
                            <th>Phase</th>
                            <th>N</th>
                            <th>Population</th>
                            <th>Primary Endpoint</th>
                            <th>Key Results</th>
                            <th>Status</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>Dose Escalation<br><small>2021</small></td>
                            <td><span class="trial-phase phase-1">Phase 1</span></td>
                            <td>~100</td>
                            <td>Healthy/HC</td>
                            <td>Safety/PK/PD</td>
                            <td>LDL-C ‚Üì65%<br>PCSK9 ‚Üì>90%</td>
                            <td><span class="trial-status status-complete">Complete</span></td>
                        </tr>
                        <tr>
                            <td>Add-on to Statins<br><small>2022</small></td>
                            <td><span class="trial-phase phase-2">Phase 2a</span></td>
                            <td>~60</td>
                            <td>Hypercholesterolemia</td>
                            <td>% LDL-C at week 14</td>
                            <td>~65% reduction</td>
                            <td><span class="trial-status status-complete">Complete</span></td>
                        </tr>
                        <tr>
                            <td>NCT05261126<br><small>2023</small></td>
                            <td><span class="trial-phase phase-2">Phase 2b</span></td>
                            <td>381</td>
                            <td>Hypercholesterolemia</td>
                            <td>% LDL-C at week 8</td>
                            <td>41-61% reduction<br>(dose-dependent)</td>
                            <td><span class="trial-status status-complete">Complete</span></td>
                        </tr>
                        <tr>
                            <td>CORALreef Lipids<br><small>NCT05952856</small></td>
                            <td><span class="trial-phase phase-3">Phase 3</span></td>
                            <td>~2,700</td>
                            <td>Hypercholesterolemia</td>
                            <td>% LDL-C at week 24</td>
                            <td>Met primary endpoint<br>>80% achieved <70 mg/dL</td>
                            <td><span class="trial-status status-complete">Complete</span></td>
                        </tr>
                        <tr>
                            <td>CORALreef HeFH<br><small>NCT05952869</small></td>
                            <td><span class="trial-phase phase-3">Phase 3</span></td>
                            <td>~300</td>
                            <td>HeFH</td>
                            <td>% LDL-C at week 24</td>
                            <td>60-65% reduction</td>
                            <td><span class="trial-status status-complete">Complete</span></td>
                        </tr>
                        <tr>
                            <td>CORALreef Outcomes<br><small>NCT06008756</small></td>
                            <td><span class="trial-phase phase-3">Phase 3</span></td>
                            <td>~14,000</td>
                            <td>ASCVD/High-risk</td>
                            <td>MACE reduction</td>
                            <td>Pending (2029)</td>
                            <td><span class="trial-status status-ongoing">Ongoing</span></td>
                        </tr>
                        <tr>
                            <td>Pediatric HeFH<br><small>NCT07058077</small></td>
                            <td><span class="trial-phase phase-2">Phase 2/3</span></td>
                            <td>~200</td>
                            <td>Pediatric HeFH</td>
                            <td>% LDL-C at week 24</td>
                            <td>Pending</td>
                            <td><span class="trial-status status-ongoing">Ongoing</span></td>
                        </tr>
                        <tr>
                            <td>Open-Label Extension<br><small>NCT06492291</small></td>
                            <td><span class="trial-phase phase-3">Phase 3</span></td>
                            <td>~3,000</td>
                            <td>Previous participants</td>
                            <td>Long-term safety</td>
                            <td>Ongoing</td>
                            <td><span class="trial-status status-ongoing">Ongoing</span></td>
                        </tr>
                    </tbody>
                </table>
                
                <div class="efficacy-chart">
                    <div class="chart-title">Phase 2b Dose-Response: LDL-C Reduction at Week 8</div>
                    <div class="bar-chart">
                        <div class="bar-group">
                            <div class="bar" style="height: 41.2%;">
                                <div class="bar-value">41.2%</div>
                            </div>
                            <div class="bar-label">6 mg QD</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 55.7%;">
                                <div class="bar-value">55.7%</div>
                            </div>
                            <div class="bar-label">12 mg QD</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar optimal" style="height: 59.7%;">
                                <div class="bar-value">59.7%</div>
                            </div>
                            <div class="bar-label">18 mg QD</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar optimal" style="height: 60.9%;">
                                <div class="bar-value">60.9%</div>
                            </div>
                            <div class="bar-label">30 mg QD</div>
                        </div>
                    </div>
                </div>
                
                <div class="efficacy-chart">
                    <div class="chart-title">Secondary Endpoints & Achievement Rates</div>
                    <div class="bar-chart">
                        <div class="bar-group">
                            <div class="bar secondary" style="height: 50%;">
                                <div class="bar-value">45-55%</div>
                            </div>
                            <div class="bar-label">ApoB Reduction</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar secondary" style="height: 50%;">
                                <div class="bar-value">45-55%</div>
                            </div>
                            <div class="bar-label">Non-HDL-C</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar lpa" style="height: 25%;">
                                <div class="bar-value">20-30%</div>
                            </div>
                            <div class="bar-label">Lp(a)</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar optimal" style="height: 80%;">
                                <div class="bar-value">>80%</div>
                            </div>
                            <div class="bar-label">Achieved<br><70 mg/dL</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 90%;">
                                <div class="bar-value">>90%</div>
                            </div>
                            <div class="bar-label">PCSK9<br>Suppression</div>
                        </div>
                    </div>
                </div>
                
                <div class="dose-response-curve">
                    <h3 class="chart-title">Dose-Response Relationship</h3>
                    <svg viewBox="0 0 600 300" style="width: 100%; height: 300px;">
                        <defs>
                            <linearGradient id="curveGradient" x1="0%" y1="0%" x2="100%" y2="0%">
                                <stop offset="0%" style="stop-color:#00539C;stop-opacity:1" />
                                <stop offset="100%" style="stop-color:#4caf50;stop-opacity:1" />
                            </linearGradient>
                        </defs>
                        
                        <!-- Grid lines -->
                        <line x1="50" y1="250" x2="550" y2="250" stroke="#e0e0e0" stroke-width="1"/>
                        <line x1="50" y1="200" x2="550" y2="200" stroke="#e0e0e0" stroke-width="1"/>
                        <line x1="50" y1="150" x2="550" y2="150" stroke="#e0e0e0" stroke-width="1"/>
                        <line x1="50" y1="100" x2="550" y2="100" stroke="#e0e0e0" stroke-width="1"/>
                        <line x1="50" y1="50" x2="550" y2="50" stroke="#e0e0e0" stroke-width="1"/>
                        
                        <!-- Axes -->
                        <line x1="50" y1="250" x2="550" y2="250" stroke="#333" stroke-width="2"/>
                        <line x1="50" y1="250" x2="50" y2="30" stroke="#333" stroke-width="2"/>
                        
                        <!-- Dose-response curve -->
                        <path d="M 100 180 Q 200 120, 300 80 T 500 70" stroke="url(#curveGradient)" stroke-width="3" fill="none"/>
                        
                        <!-- Data points -->
                        <circle cx="100" cy="180" r="5" fill="#00539C"/>
                        <circle cx="200" cy="120" r="5" fill="#00539C"/>
                        <circle cx="300" cy="80" r="5" fill="#4caf50"/>
                        <circle cx="400" cy="75" r="5" fill="#4caf50"/>
                        <circle cx="500" cy="70" r="5" fill="#4caf50"/>
                        
                        <!-- Labels -->
                        <text x="100" y="270" text-anchor="middle" font-size="12">6mg</text>
                        <text x="200" y="270" text-anchor="middle" font-size="12">12mg</text>
                        <text x="300" y="270" text-anchor="middle" font-size="12">18mg</text>
                        <text x="400" y="270" text-anchor="middle" font-size="12">24mg</text>
                        <text x="500" y="270" text-anchor="middle" font-size="12">30mg</text>
                        
                        <text x="30" y="255" text-anchor="middle" font-size="12">0%</text>
                        <text x="30" y="205" text-anchor="middle" font-size="12">20%</text>
                        <text x="30" y="155" text-anchor="middle" font-size="12">40%</text>
                        <text x="30" y="105" text-anchor="middle" font-size="12">60%</text>
                        <text x="30" y="55" text-anchor="middle" font-size="12">80%</text>
                        
                        <!-- Plateau annotation -->
                        <rect x="280" y="45" width="240" height="40" fill="rgba(76, 175, 80, 0.1)" rx="5"/>
                        <text x="400" y="65" text-anchor="middle" font-size="13" fill="#2e7d32" font-weight="600">Efficacy Plateau</text>
                        <text x="400" y="80" text-anchor="middle" font-size="11" fill="#666">18-30mg optimal range</text>
                    </svg>
                </div>
            </div>
            
            <!-- Safety Tab -->
            <div id="safety" class="tab-content">
                <div class="highlight-box">
                    <div class="highlight-title">Safety Overview</div>
                    <div class="highlight-content">
                        ~4,000 patients exposed by 2025 with placebo-like safety profile. No black-box warnings anticipated. 
                        Acts extracellularly without CYP metabolism, minimizing drug interactions and organ toxicity. 
                        No injection site reactions (oral administration advantage).
                    </div>
                </div>
                
                <div class="safety-grid">
                    <div class="safety-card">
                        <div class="safety-percentage">6-8%</div>
                        <div class="safety-label">Headache</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage">5-7%</div>
                        <div class="safety-label">Nasopharyngitis</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage">4-6%</div>
                        <div class="safety-label">GI symptoms<br>(mild)</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage"><2%</div>
                        <div class="safety-label">Serious AEs</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage">1-2%</div>
                        <div class="safety-label">Discontinuation</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage"><1%</div>
                        <div class="safety-label">Anti-drug<br>antibodies</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage"><3%</div>
                        <div class="safety-label">Myalgia</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage">0%</div>
                        <div class="safety-label">Injection site<br>reactions</div>
                    </div>
                </div>
                
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">‚úì</div>
                            No Safety Signals
                        </div>
                        <ul class="info-list">
                            <li>No liver enzyme elevations</li>
                            <li>No CK elevations</li>
                            <li>No glucose/diabetes signal</li>
                            <li>No blood pressure effects</li>
                            <li>No dose-related GI issues</li>
                            <li>No immunogenicity concerns</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üß†</div>
                            Neurocognitive Safety
                        </div>
                        <ul class="info-list">
                            <li>No signals in trials</li>
                            <li>~30% achieved LDL <25 mg/dL safely</li>
                            <li>Confusion/amnesia <1%</li>
                            <li>Consistent with PCSK9 class data</li>
                            <li>No harm even at LDL <15 mg/dL</li>
                            <li>Oral route unlikely to differ</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üíä</div>
                            Unique Safety Advantages
                        </div>
                        <ul class="info-list">
                            <li>No injection site reactions (oral)</li>
                            <li>GI tolerability generally good</li>
                            <li>No CYP metabolism interactions</li>
                            <li>Acts extracellularly only</li>
                            <li>Low immunogenicity (<1%)</li>
                            <li>Peptide-specific design</li>
                        </ul>
                    </div>
                </div>
            </div>
            
            <!-- Commercial Tab -->
            <div id="commercial" class="tab-content">
                <div class="commercial-section">
                    <div class="price-projection">
                        <div class="price-range">$4,000 - $6,000</div>
                        <div class="price-comparison">Projected annual cost (vs $5,800 for injectable mAbs)</div>
                    </div>
                    
                    <div class="market-metrics">
                        <div class="metric-card">
                            <div class="metric-value">$2-8B</div>
                            <div class="metric-label">Market potential by 2032</div>
                        </div>
                        <div class="metric-card">
                            <div class="metric-value">~50%</div>
                            <div class="metric-label">Expected real-world adherence</div>
                        </div>
                        <div class="metric-card">
                            <div class="metric-value">80%</div>
                            <div class="metric-label">Initial PA denial rate</div>
                        </div>
                        <div class="metric-card">
                            <div class="metric-value">10x</div>
                            <div class="metric-label">Broader prescriber base</div>
                        </div>
                    </div>
                </div>
                
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üí∞</div>
                            Reimbursement Strategy
                        </div>
                        <ul class="info-list">
                            <li>Initial restriction to high-risk/statin-intolerant</li>
                            <li>Similar PA requirements to mAbs initially</li>
                            <li>Pharmacy benefit simplifies vs medical</li>
                            <li>Outcomes data (2029) key for expansion</li>
                            <li>Volume-based pricing possible</li>
                            <li>Digital adherence programs planned</li>
                        </ul>
                    </div>
                    
                   <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üè•</div>
                            Market Access Advantages
                        </div>
                        <ul class="info-list">
                            <li>Broad GP prescribing (not specialist-only)</li>
                            <li>No injection training required</li>
                            <li>At-home self-administration</li>
                            <li>Simpler distribution via pharmacies</li>
                            <li>Potential for mail-order delivery</li>
                            <li>Lower infrastructure requirements</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üéØ</div>
                            Competitive Positioning
                        </div>
                        <ul class="info-list">
                            <li>First-mover advantage in oral PCSK9</li>
                            <li>Most significant threat to inclisiran</li>
                            <li>AstraZeneca's AZD0780 following</li>
                            <li>Merck's CV marketing expertise</li>
                            <li>Potential for fixed-dose combos</li>
                            <li>Volume play vs premium pricing</li>
                        </ul>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Commercial Strategy</div>
                    <div class="highlight-content">
                        MK-0616 could transform PCSK9 inhibition from specialist injectable to primary care oral therapy. 
                        Success depends on competitive pricing, managing adherence challenges, and demonstrating CV outcomes by 2029. 
                        Merck's history with blockbuster CV drugs (Zetia, Vytorin) and large Phase 3 program indicate 
                        commitment to broad market penetration. Pharmacy benefit distribution avoids buy-and-bill complexities 
                        that challenged inclisiran's US launch.
                    </div>
                </div>
            </div>
            
            <!-- Pipeline Tab -->
            <div id="pipeline" class="tab-content">
                <div class="pipeline-timeline">
                    <div class="pipeline-track">
                        <div class="pipeline-progress"></div>
                    </div>
                    <div class="pipeline-milestone" style="left: 0;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Preclinical</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 20%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Phase 1</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 40%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Phase 2</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 60%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Phase 3</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 75%;">
                        <div class="milestone-dot" style="background: #00539C;"></div>
                        <div class="milestone-label"><strong>Current</strong></div>
                    </div>
                    <div class="pipeline-milestone" style="left: 85%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Filing<br>(2026)</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 100%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Launch<br>(2027)</div>
                    </div>
                </div>
                
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üîÆ</div>
                            Near-Term Development
                        </div>
                        <ul class="info-list">
                            <li>NDA filing expected mid-2026</li>
                            <li>Potential approval 2027</li>
                            <li>First oral PCSK9i to market</li>
                            <li>Pediatric indication development</li>
                            <li>Open-label extension ongoing</li>
                            <li>CORALreef Outcomes through 2029</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üöÄ</div>
                            Pipeline Expansion
                        </div>
                        <ul class="info-list">
                            <li>Fixed-dose combos (+ ezetimibe/statin)</li>
                            <li>Primary prevention studies possible</li>
                            <li>All-in-one lipid pill potential</li>
                            <li>Patent protection to late 2030s</li>
                            <li>Manufacturing scalability advantage</li>
                            <li>Global expansion post-FDA</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">‚öîÔ∏è</div>
                            Competitive Landscape
                        </div>
                        <ul class="info-list">
                            <li>AstraZeneca's AZD0780 ~1-2 years behind</li>
                            <li>Multiple oral PCSK9i by 2030</li>
                            <li>Gene therapies distant threat (2030s)</li>
                            <li>Biosimilar mAbs coming ~2028</li>
                            <li>Inclisiran's biannual advantage</li>
                            <li>Price competition expected</li>
                        </ul>
                    </div>
                </div>
                
                <div class="game-changer-banner" style="background: linear-gradient(135deg, #ff9800 0%, #f57c00 100%);">
                    <h3>üèÜ Market Transformation Potential</h3>
                    <p>MK-0616 heralds a convenience battle: pills versus injections. Historically in medicine, pills win due to 
                    patient and provider preference when efficacy and safety are equivalent. If MK-0616 maintains its stellar 
                    trial results, it could become the dominant PCSK9 inhibitor by 2030, relegating injectables to specific 
                    niches (adherence-challenged patients). The ability to prescribe through primary care could expand the 
                    PCSK9 market 5-10x beyond current specialist-driven injectable use.</p>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Long-Term Outlook</div>
                    <div class="highlight-content">
                        By 2030, oral PCSK9 inhibitors likely to dominate market if adherence challenges are managed. 
                        MK-0616's first-mover advantage critical for establishing market share before competition. 
                        Merck's development of fixed-dose combinations could create an "all-in-one" lipid management pill. 
                        Success of CORALreef Outcomes trial (2029) will determine whether oral PCSK9i can match 
                        injectable outcomes and secure broad reimbursement. Patent life to late 2030s provides 
                        sustainable revenue window before generic competition.
                    </div>
                </div>
                
                <div class="adherence-comparison">
                    <strong>Critical Success Factor:</strong> Managing the adherence paradox - while daily pills are more 
                    convenient than injections, real-world adherence to daily medications is typically only ~50% at 1 year. 
                    Merck's investment in digital adherence tools, patient support programs, and potentially smart packaging 
                    will be essential to realize the full potential of oral PCSK9 inhibition. The convenience of at-home 
                    administration must translate to sustained daily compliance to match the guaranteed effect of supervised 
                    biannual inclisiran injections.
                </div>
            </div>
        </div>
    </div>
    
    <script>
        function showTab(tabName) {
            // Hide all tabs
            const tabs = document.querySelectorAll('.tab-content');
            tabs.forEach(tab => tab.classList.remove('active'));
            
            // Remove active class from all nav tabs
            const navTabs = document.querySelectorAll('.nav-tab');
            navTabs.forEach(tab => tab.classList.remove('active'));
            
            // Show selected tab
            document.getElementById(tabName).classList.add('active');
            
            // Add active class to clicked nav tab
            event.target.classList.add('active');
        }
        
        // Animate bars on scroll
        const observerOptions = {
            threshold: 0.5
        };
        
        const observer = new IntersectionObserver((entries) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    const bars = entry.target.querySelectorAll('.bar');
                    bars.forEach((bar, index) => {
                        setTimeout(() => {
                            bar.style.animation = 'growUp 1s ease-out';
                        }, index * 100);
                    });
                }
            });
        }, observerOptions);
        
        document.querySelectorAll('.bar-chart').forEach(el => {
            observer.observe(el);
        });
        
        // Animate progress bar
        const progressObserver = new IntersectionObserver((entries) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    const progress = entry.target.querySelector('.pipeline-progress');
                    if (progress) {
                        progress.style.animation = 'progressGrow 2s ease-out';
                    }
                }
            });
        }, observerOptions);
        
        document.querySelectorAll('.pipeline-timeline').forEach(el => {
            progressObserver.observe(el);
        });
    </script>
    
    <style>
        /* Ensure all styles from the original are included */
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            min-height: 100vh;
            padding: 20px;
        }
        
        .container {
            max-width: 1400px;
            margin: 0 auto;
            background: white;
            border-radius: 20px;
            box-shadow: 0 20px 60px rgba(0,0,0,0.3);
            overflow: hidden;
        }
        
        .header {
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            color: white;
            padding: 40px;
            position: relative;
            overflow: hidden;
        }
        
        .header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -10%;
            width: 40%;
            height: 200%;
            background: rgba(255,255,255,0.08);
            transform: rotate(45deg);
        }
        
        .drug-title {
            position: relative;
            z-index: 1;
        }
        
        .drug-name {
            font-size: 48px;
            font-weight: bold;
            margin-bottom: 10px;
            text-shadow: 2px 2px 4px rgba(0,0,0,0.2);
        }
        
        .drug-generic {
            font-size: 28px;
            opacity: 0.95;
            margin-bottom: 10px;
        }
        
        .drug-subtitle {
            font-size: 22px;
            opacity: 0.9;
            margin-bottom: 5px;
        }
        
        .drug-company {
            font-size: 20px;
            opacity: 0.85;
        }
        
        .status-badge {
            display: inline-block;
            background: linear-gradient(135deg, #ff9800 0%, #f57c00 100%);
            padding: 10px 20px;
            border-radius: 25px;
            margin-top: 20px;
            font-weight: 600;
            font-size: 16px;
            box-shadow: 0 4px 10px rgba(0,0,0,0.2);
            animation: pulse 2s infinite;
        }
        
        @keyframes pulse {
            0%, 100% { transform: scale(1); }
            50% { transform: scale(1.05); }
        }
        
        .first-in-class {
            display: inline-block;
            background: linear-gradient(135deg, #4caf50 0%, #2e7d32 100%);
            padding: 8px 16px;
            border-radius: 20px;
            margin-left: 10px;
            font-size: 14px;
            font-weight: 600;
        }
        
        .nav-tabs {
            display: flex;
            background: #f8f9fa;
            border-bottom: 2px solid #e0e0e0;
            overflow-x: auto;
        }
        
        .nav-tab {
            padding: 15px 30px;
            cursor: pointer;
            border: none;
            background: transparent;
            font-size: 16px;
            font-weight: 600;
            color: #666;
            transition: all 0.3s;
            white-space: nowrap;
        }
        
        .nav-tab:hover {
            background: rgba(0, 83, 156, 0.1);
        }
        
        .nav-tab.active {
            color: #00539C;
            border-bottom: 3px solid #00539C;
            margin-bottom: -2px;
        }
        
        .content-area {
            padding: 40px;
        }
        
        .tab-content {
            display: none;
            animation: fadeIn 0.5s;
        }
        
        .tab-content.active {
            display: block;
        }
        
        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }
        
        .game-changer-banner {
            background: linear-gradient(135deg, #4caf50 0%, #2e7d32 100%);
            color: white;
            padding: 25px;
            border-radius: 15px;
            margin-bottom: 30px;
            box-shadow: 0 5px 20px rgba(76, 175, 80, 0.3);
        }
        
        .game-changer-banner h3 {
            font-size: 24px;
            margin-bottom: 10px;
        }
        
        .info-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 30px;
            margin: 30px 0;
        }
        
        .info-card {
            background: white;
            border-radius: 15px;
            padding: 25px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .info-card-title {
            font-size: 18px;
            font-weight: bold;
            color: #333;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
        }
        
        .info-icon {
            width: 30px;
            height: 30px;
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            margin-right: 10px;
            color: white;
            font-size: 14px;
        }
        
        .info-list {
            list-style: none;
        }
        
        .info-list li {
            padding: 8px 0;
            border-bottom: 1px solid #f0f0f0;
            color: #666;
            font-size: 14px;
        }
        
        .info-list li:last-child {
            border-bottom: none;
        }
        
        .highlight-box {
            background: linear-gradient(135deg, rgba(0, 83, 156, 0.1) 0%, rgba(0, 58, 112, 0.1) 100%);
            border-left: 4px solid #00539C;
            padding: 20px;
            border-radius: 8px;
            margin: 20px 0;
        }
        
        .highlight-title {
            font-weight: bold;
            color: #00539C;
            margin-bottom: 10px;
        }
        
        .highlight-content {
            color: #555;
            line-height: 1.6;
        }
        
        .pipeline-timeline {
            position: relative;
            padding: 20px 0;
            margin: 30px 0;
        }
        
        .pipeline-track {
            height: 8px;
            background: #e0e0e0;
            border-radius: 4px;
            position: relative;
        }
        
        .pipeline-progress {
            height: 100%;
            background: linear-gradient(90deg, #00539C 0%, #003A70 100%);
            border-radius: 4px;
            width: 75%;
            position: relative;
            animation: progressGrow 2s ease-out;
        }
        
        @keyframes progressGrow {
            from { width: 0; }
        }
        
        .pipeline-milestone {
            position: absolute;
            top: -40px;
            transform: translateX(-50%);
            text-align: center;
            white-space: nowrap;
        }
        
        .milestone-dot {
            width: 16px;
            height: 16px;
            background: white;
            border: 3px solid #00539C;
            border-radius: 50%;
            margin: 0 auto 5px;
        }
        
        .milestone-label {
            font-size: 12px;
            color: #666;
        }
        
        .adherence-comparison {
            background: #fff3cd;
            border-left: 4px solid #ff9800;
            padding: 20px;
            border-radius: 8px;
            margin: 20px 0;
        }
        
        .commercial-section {
            background: #f8f9fa;
            border-radius: 15px;
            padding: 30px;
            margin: 20px 0;
        }
        
        .price-projection {
            text-align: center;
            margin: 30px 0;
        }
        
        .price-range {
            font-size: 36px;
            font-weight: bold;
            background: linear-gradient(135deg, #00539C 0%, #003A70 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }
        
        .price-comparison {
            font-size: 16px;
            color: #666;
            margin-top: 10px;
        }
        
        .market-metrics {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            margin: 30px 0;
        }
        
        .metric-card {
            background: white;
            padding: 20px;
            border-radius: 12px;
            text-align: center;
            border-top: 4px solid #00539C;
        }
        
        .metric-value {
            font-size: 28px;
            font-weight: bold;
            color: #00539C;
            margin-bottom: 5px;
        }
        
        .metric-label {
            font-size: 14px;
            color: #666;
        }
    </style>
</body>
</html>